Z6·尊龙凯时「中国」官方网站z6尊龙

|
EN
|
EN
EN
  • 业务咨询

    中国:

    Email: marketing@kangtya.com

    业务咨询专线:400-780-8018

    (仅限服务咨询,其他事宜请拨打川沙总部电话)

    川沙总部电话: +86 (21) 5859-1500

    海外:

    +1(626)986-9880(U.S. - West Coast)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

在线留言×
点击切换
Customer Center
客户中心

设计合成一种新型选择性的口服有效苏氨酸酪氨酸激酶 (TTK) 抑制剂,PK研究均通过z6尊龙进行

2023-06-28
|
访问量:

7-TTK-inhibition-1.jpg

Threonine tyrosine kinase (TTK), a dual-specificity protein kinase, acts as a core component of the spindle assembly checkpoint and plays a crucial role in accurate separation of sister chromatids during mitosis to avoid aneuploidy. TTK inhibition is an attractive wide-spectrum strategy for cancer therapy. Researchers designed and synthesized a series of pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable TTK inhibitors. All the pharmacokinetic studies were carried out by Medicilon.

Compounds 5o exhibits strong binding affinity to TTK with a Kd value of 0.15 nM.

Compound 5o demonstrates good oral pharmacokinetic properties.

Reference

Minhao Huang, et al. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors. Eur J Med Chem. 2021 Feb 5;211:113023. doi: 10.1016/j.ejmech.2020.113023.

相关新闻
×
搜索验证
点击切换
网站首页
z6尊龙